Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;270(7):3654-3666.
doi: 10.1007/s00415-023-11706-1. Epub 2023 Apr 8.

Migraine: from pathophysiology to treatment

Francesca Puledda  1 , Elisa Martins Silva  2 , Kanokrat Suwanlaong  3 , Peter J Goadsby  4   5
Affiliations
Review

Migraine: from pathophysiology to treatment

Francesca Puledda et al. J Neurol. 2023 Jul.

Abstract

Migraine is an extremely disabling, common neurological disorder characterized by a complex neurobiology, involving a series of central and peripheral nervous system areas and networks. A growing increase in the understanding of migraine pathophysiology in recent years has facilitated translation of that knowledge into novel treatments, which are currently becoming available to patients in many parts of the world and are substantially changing the clinical approach to the disease. In the first part of this review, we will provide an up to date overview of migraine pathophysiology by analyzing the anatomy and function of the main regions involved in the disease, focusing on how these give rise to the plethora of symptoms characterizing the attacks and overall disease. The second part of the paper will discuss the novel therapeutic agents that have emerged for the treatment of migraine, including molecules targeting calcitonin gene-related peptide (gepants and monoclonal antibodies), serotonin 5-HT1F receptor agonists (ditans) and non-invasive neuromodulation, as well as providing a brief overview of new evidence for classic migraine treatments.

Keywords: CGRP; Migraine; Neuromodulation; Pathophysiology; Treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Global Burden of Disease Study 2013 Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England) 2013;386(9995):743–800. - PMC - PubMed
    1. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine—a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622. doi: 10.1152/physrev.00034.2015. - DOI - PMC - PubMed
    1. Lipton RB, Dodick DW, Ailani J, McGill L, Hirman J, Cady R. Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: a novel patient-centered outcome. Headache. 2021;61(5):766–776. doi: 10.1111/head.14120. - DOI - PMC - PubMed
    1. Lampl C, Thomas H, Stovner LJ, Tassorelli C, Katsarava Z, Laínez JM, et al. Interictal burden attributable to episodic headache: findings from the Eurolight project. J Headache Pain. 2016;17:9. doi: 10.1186/s10194-016-0599-8. - DOI - PMC - PubMed
    1. Dodick DW. A Phase-by-phase review of migraine pathophysiology. Headache. 2018;58(Suppl 1):4–16. doi: 10.1111/head.13300. - DOI - PubMed

MeSH terms

Substances